BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 35365067)

  • 1. Impact of renin-angiotensin-aldosterone-system inhibitor drugs on mortality in patients with atrial fibrillation and hypertension.
    Xu W; Yang YM; Zhu J; Wu S; Wang J; Zhang H; Shao XH
    BMC Cardiovasc Disord; 2022 Apr; 22(1):141. PubMed ID: 35365067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation: A Nationwide Cohort Study.
    Hsieh YC; Hung CY; Li CH; Liao YC; Huang JL; Lin CH; Wu TJ
    Medicine (Baltimore); 2016 May; 95(20):e3721. PubMed ID: 27196491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on one-year outcomes of patients with atrial fibrillation: insights from a multicenter registry study in China.
    Lyu SQ; Yang YM; Zhu J; Wang J; Wu S; Ren JM; Zhang H; Shao XH
    J Geriatr Cardiol; 2020 Dec; 17(12):750-758. PubMed ID: 33424942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between renin-angiotensin-aldosterone system blockade and clinical outcomes in patients with hypertension: real-world observation from a nationwide hypertension cohort.
    Park CS; Kim B; Rhee TM; Lee HJ; Lee HS; Park JB; Kim YJ; Han KD; Kim HK
    Clin Res Cardiol; 2023 Nov; 112(11):1577-1586. PubMed ID: 36867200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-angiotensin system inhibition is associated with reduced risk of left atrial appendage thrombosis formation in patients with atrial fibrillation.
    Suo Y; Zhang Y; Wang Y; Yuan M; Kariyawasam S; Tse G; Liu T; Fu H; Li G
    Cardiol J; 2018; 25(5):611-620. PubMed ID: 28980280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis.
    Lin TT; Yang YH; Liao MT; Tsai CT; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
    Kidney Int; 2015 Aug; 88(2):378-85. PubMed ID: 25807037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of renin-angiotensin-aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study.
    Sato K; White N; Fanning JP; Obonyo N; Yamashita MH; Appadurai V; Ciullo A; May M; Worku ET; Helms L; Ohshimo S; Juzar DA; Suen JY; Bassi GL; Fraser JF; Arora RC;
    BMC Cardiovasc Disord; 2022 Mar; 22(1):123. PubMed ID: 35321649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
    Lee J; Lee S
    Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-angiotensin-aldosterone blockade reduces atrial fibrillation in hypertrophic cardiomyopathy.
    Huang CY; Yang YH; Lin LY; Tsai CT; Hwang JJ; Chen PC; Lin JL
    Heart; 2018 Aug; 104(15):1276-1283. PubMed ID: 29371376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin-angiotensin-system modulators and the incidence of atrial fibrillation following hospitalization for coronary artery disease.
    Singh JP; Kulik A; Levin R; Ellinor PT; Ruskin J; Avorn J; Choudhry NK
    Europace; 2012 Sep; 14(9):1287-93. PubMed ID: 22539600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-Angiotensin System Inhibitors Prognostic Benefit in Older Patients with Atrial Fibrillation.
    Cespón-Fernández M; Raposeiras-Roubín S; Abu-Assi E; Melendo-Viu M; García-Campo E; Íñiguez-Romo A
    J Am Med Dir Assoc; 2021 Oct; 22(10):2190-2195. PubMed ID: 33607060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation.
    Lip GY; Frison L; Grind M
    J Intern Med; 2007 Jun; 261(6):577-86. PubMed ID: 17547713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Divergent Cardiovascular Effects of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Myocardial Infarction and Death.
    Strauss MH; Hall AS
    Prog Cardiovasc Dis; 2016; 58(5):473-82. PubMed ID: 26586276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the withdrawal of renin-angiotensin-aldosterone inhibitors on mortality in COVID-19 patients.
    Caro-Codón J; Rey JR; Iniesta AM; Rosillo SO; Castrejon-Castrejon S; Rodriguez-Sotelo L; Garcia-Veas JM; Marco I; Martinez LA; Martin-Polo L; Merino C; Martinez-Cossiani M; Buño A; Gonzalez-Valle L; Herrero A; López-de-Sá E; Merino JL;
    Rev Port Cardiol; 2022 Oct; 41(10):823-830. PubMed ID: 35784098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-Angiotensin-Aldosterone System Blockade after AKI with or without Recovery among US Veterans with Diabetic Kidney Disease.
    Murphy DP; Wolfson J; Reule S; Johansen KL; Ishani A; Drawz PE
    J Am Soc Nephrol; 2023 Oct; 34(10):1721-1732. PubMed ID: 37545022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin-angiotensin-aldosterone system inhibitors and mortality risk in elderly patients with atrial fibrillation. Insights from the nationwide START registry.
    Menichelli D; Poli D; Antonucci E; Palareti G; Pignatelli P; Pastori D;
    Eur J Intern Med; 2024 Jan; 119():84-92. PubMed ID: 37648584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
    Zhang P; Zhu L; Cai J; Lei F; Qin JJ; Xie J; Liu YM; Zhao YC; Huang X; Lin L; Xia M; Chen MM; Cheng X; Zhang X; Guo D; Peng Y; Ji YX; Chen J; She ZG; Wang Y; Xu Q; Tan R; Wang H; Lin J; Luo P; Fu S; Cai H; Ye P; Xiao B; Mao W; Liu L; Yan Y; Liu M; Chen M; Zhang XJ; Wang X; Touyz RM; Xia J; Zhang BH; Huang X; Yuan Y; Loomba R; Liu PP; Li H
    Circ Res; 2020 Jun; 126(12):1671-1681. PubMed ID: 32302265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
    Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
    Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.